Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 103, Issue 7, 2011, Pages 704-715

  Wang, Feng ^a   Wang, Liu Xing ^a   Li, Sheng Lei ^a   Li, Ke ^a   He, Wei ^a   Liu, Hong Tao ^b   Fan, Qing Xia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

apoptosis; cell cycle; esophageal squamous cell carcinoma; RNA interference; stathmin

Indexed keywords

CASPASE 3; DNA; PROTEIN BCL 2; SHORT HAIRPIN RNA; STATHMIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, NUDE; PHENOTYPE; PLASMIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; STATHMIN; TRANSFECTION;

EID: 79955470704     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21870     Document Type: Article

References (40)

1. Andersen SS,: Spindle assembly and the art of regulating microtubule dynamics by MAPs and stathmin/Op18. Trends Cell Biol 2000; 10: 261-267. (Pubitemid 30387030)
2. Charbaut E, Curmi PA, Ozon S, et al.: Stathmin family proteins display specific molecular and tubulin binding properties. J Biol Chem 2001; 276: 16146-16154.
3. Cassimeris L,: The oncoprotein 18/stathmin family of microtubule destabilizers. J Biol Inorg Chem 2002; 14: 18-24. (Pubitemid 34131652)
4. Wallon G, Rappsilber J, Mann M, et al.: Model for stathmin/OP18 binding to tubulin. EMBO J 2000; 19: 213-222. (Pubitemid 30042703)
5. Steinmetz MO,: Structure and, thermodynamics of the tubulin-stathmin interaction. J Struct Biol 2007; 158: 137-147.
6. Brattsand G,: Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000; 83: 311-318. (Pubitemid 30453569)
7. Hsieh SY, Huang SF, Yu MC, et al.: Stathmin 1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010; 49: 476-487.
8. Price DK, Ball JR, Bahrani-Mostafavi Z, et al.: The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 2000; 18: 722-730.
9. Wei SH, Lin F, Wang X, et al.: Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem 2008; 110: 59-65.
10. Mistry SJ, Benham CJ, Atweh GF,: Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001; 11: 41-49. (Pubitemid 32199393)
11. Iancu C, Mistry SJ, Arkin S, et al.: Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001; 114: 909-916. (Pubitemid 32266262)
12. Novina CD, Sharp PA,: The RNAi revolution. Nature 2004; 430: 161-164. (Pubitemid 38902417)
13. Wong RP, Ng P, Dedhar S, et al.: The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther 2007; 6: 1692-1700. (Pubitemid 46954045)
14. Nicola C, Lala PK, Chakraborty C,: Prostaglandin E2-mediated migration of human trophoblast requires RAC1 and CDC42. Biol Reprod 2008; 78: 976-982. (Pubitemid 351749292)
15. Mistry SJ, Atweh GF,: Role of stathmin in the regulation of the mitotic spindle: Potential applications in cancer therapy. Mt Sinai J Med 2002; 69: 299-304. (Pubitemid 35244131)
16. Rubin CI, Atweh GF,: The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004; 93: 242-250. (Pubitemid 44264202)
17. Segerman B, Larsson N, Holmfeldt P, et al.: Mutational analysis of op18/stathmin-tubulin-interacting surfaces. Binding cooperativity controls tubulin GTP hydrolysis in the ternary complex. J Biol Chem 2000; 275: 35759-35766.
18. Rana S, Maples PB, Senzer N, et al.: Stathmin 1: A novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008; 8: 1461-1470.
19. Zhang HZ, Wang Y, Gao P, et al.: Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 2006; 5: 1457-1461.
20. Baldassarre G, Belletti B, Nicoloso MS, et al.: p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7: 51-63. (Pubitemid 40126382)
21. Belletti B, Nicoloso MS, Schiappacassi M, et al.: Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008; 19: 2003-2013.
22. Niethammer P, Bastiaens P, Karsenti E,: Stathmin-tubulin interaction gradients in motile and mitotic cells. Science 2004; 303: 1862-1866. (Pubitemid 38374877)
23. Chen G, Wang H, Gharib TG, et al.: Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003; 2: 107-116.
24. Kouzu Y, Uzawa K, Koike H, et al.: Overexpression of stathmin in oral squamous-cell carcinoma: Correlation with tumour progression and poor prognosis. Br J Cancer 2006; 94: 717-723. (Pubitemid 43361904)
25. Elbashir SM, Lendeckel W, Tuschl T,: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200. (Pubitemid 32107664)
26. Tomari Y, Matranga C, Haley B, et al.: A protein sensor for siRNA asymmetry. Science 2004; 306: 1377-1380. (Pubitemid 39532515)
27. Hingorani SR, Jacobetz MA, Robertson GP, et al.: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198-5202. (Pubitemid 37139827)
28. Brummelkamp TR, Bernards R, Agami R,: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247. (Pubitemid 41043979)
29. Takei Y, Kadomatsu K, Yuzawa Y, et al.: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-3370. (Pubitemid 38657905)
30. Burz C, Berindan-Neagoe I, Balacescu O, et al.: Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol 2009; 9: 1-11.
31. Haupt S, Berger M, Goldberg Z, et al.: Apoptosis-the p53 network. J Cell Sci 2003; 116: 4077-4085.
32. Brunelle JK, Letai A,: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-441.
33. Wheatley SP, McNeish IA,: Survivin: A protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005; 247: 35-88. (Pubitemid 41774364)
34. Altieri DC,: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615. (Pubitemid 44692469)
35. Li F, Ambrosini G, Chu EY, et al.: Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 1998; 396: 580-584. (Pubitemid 28563719)
36. Fujie Y, Yamamoto H, Ngan CY, et al.: Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-463. (Pubitemid 41309198)
37. Bergstralh DT, Ting JP,: Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006; 32: 166-179.
38. Mollinedo F, Gajate C,: Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8: 413-450. (Pubitemid 37247987)
39. Bhalla KN,: Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22: 9075-9086. (Pubitemid 38121708)
40. Zhang Y, Xiong J, Wang J, et al.: Regulation of melanocyte apoptosis by Stathmin 1 expression. BMB Rep 2008; 41: 765-770.